Symbols / ORIC
ORIC Chart
About
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.31B |
| Enterprise Value | 1.07B | Income | -129.47M | Sales | — |
| Book/sh | 3.90 | Cash/sh | 2.81 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -8.54 | PEG | — |
| P/S | — | P/B | 3.44 | P/C | — |
| EV/EBITDA | -7.51 | EV/Sales | — | Quick Ratio | 13.79 |
| Current Ratio | 14.13 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.71 | EPS next Y | -1.57 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-04 | ROA | -26.17% |
| ROE | -41.27% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 97.39M |
| Shs Float | 66.57M | Short Float | 22.51% | Short Ratio | 12.10 |
| Short Interest | — | 52W High | 14.93 | 52W Low | 3.90 |
| Beta | — | Avg Volume | 1.49M | Volume | 4.66M |
| Target Price | $21.23 | Recom | Strong_buy | Prev Close | $11.71 |
| Price | $13.42 | Change | 14.60% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.23
Mean price target
2. Current target
$13.42
Latest analyst target
3. DCF / Fair value
$-16.78
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.42
Low
$15.00
High
$25.00
Mean
$21.23
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | main | Citigroup | Buy → Buy | $17 |
| 2026-02-24 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2026-02-24 | reit | Wedbush | Outperform → Outperform | $20 |
| 2026-01-13 | reit | Wedbush | Outperform → Outperform | $20 |
| 2026-01-07 | init | Piper Sandler | — → Overweight | $22 |
| 2025-12-08 | main | Wells Fargo | Overweight → Overweight | $25 |
| 2025-12-08 | reit | Wedbush | Outperform → Outperform | $20 |
| 2025-11-20 | init | Evercore ISI Group | — → Outperform | $25 |
| 2025-11-18 | init | Wolfe Research | — → Peer Perform | — |
| 2025-11-18 | main | JP Morgan | Overweight → Overweight | $20 |
| 2025-11-17 | main | Citigroup | Buy → Buy | $16 |
| 2025-11-14 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-11-14 | main | Wells Fargo | Overweight → Overweight | $19 |
| 2025-11-14 | main | Oppenheimer | Outperform → Outperform | $15 |
| 2025-08-14 | main | JP Morgan | Overweight → Overweight | $17 |
| 2025-08-14 | main | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-08-13 | reit | Guggenheim | Buy → Buy | $18 |
| 2025-07-08 | init | Ladenburg Thalmann | — → Buy | $15 |
| 2025-05-19 | main | JP Morgan | Overweight → Overweight | $20 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $22 |
- $ORIC stock is up 11% today. Here's what we see in our data. - Quiver Quantitative ue, 24 Feb 2026 19
- HC Wainwright Forecasts Strong Price Appreciation for Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat ue, 24 Feb 2026 16
- Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 85% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews Fri, 20 Feb 2026 15
- ORIC: Citigroup Raises Price Target to $17, Maintains Buy Rating - GuruFocus ue, 24 Feb 2026 21
- Oric Pharmaceuticals Launches New 2026 ATM Share Program - TipRanks Mon, 23 Feb 2026 22
- ORIC Pharmaceuticals (NASDAQ: ORIC) boosts 2025 cash runway with $264M raise - Stock Titan Mon, 23 Feb 2026 21
- H.C. Wainwright raises ORIC Pharmaceuticals price target on trial progress By Investing.com - Investing.com UK Wed, 25 Feb 2026 12
- Oric Pharmaceuticals, Inc. SEC 10-K Report - TradingView Mon, 23 Feb 2026 21
- Oric Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily hu, 19 Feb 2026 08
- ORIC Pharmaceuticals (ORIC) Sees Price Target Raised to $25 by HC Wainwright & Co. | ORIC Stock News - GuruFocus ue, 24 Feb 2026 16
- ORIC Cancer Pipeline Progress And Big Pharma Partnerships Reshape Risk Profile - simplywall.st Mon, 23 Feb 2026 21
- ORIC Pharmaceuticals Reports Promising Phase 1b Data for Rinzimetostat and Enozertinib, Completes $264 Million Funding Round - Quiver Quantitative Mon, 23 Feb 2026 21
- Evercore Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛 ue, 24 Feb 2026 16
- Oric Pharmaceuticals' (ORIC) "Outperform" Rating Reiterated at Wedbush - MarketBeat ue, 24 Feb 2026 14
- Oppenheimer reiterates Outperform on ORIC stock, $15 target - Investing.com South Africa ue, 24 Feb 2026 06
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6700 | 80431.0 | — | Sale at price 12.00 per share. | HEYMAN RICHARD A | Director | — | 2026-01-16 00:00:00 | D/I |
| 1 | 10720 | 97129.0 | — | Sale at price 9.06 per share. | MULTANI PRATIK S | Officer | — | 2025-12-16 00:00:00 | D |
| 2 | 33374 | 302368.0 | — | Sale at price 9.06 per share. | CHACKO JACOB M | Chief Executive Officer | — | 2025-12-16 00:00:00 | D |
| 3 | 10720 | 97127.0 | — | Sale at price 9.06 per share. | PISCITELLI DOMINIC G. | Chief Financial Officer | — | 2025-12-16 00:00:00 | D |
| 4 | 29333 | nan | — | — | MULTANI PRATIK S | Officer | — | 2025-12-15 00:00:00 | D |
| 5 | 83666 | nan | — | — | CHACKO JACOB M | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 6 | 29333 | nan | — | — | PISCITELLI DOMINIC G. | Chief Financial Officer | — | 2025-12-15 00:00:00 | D |
| 7 | 10000 | 79000.0 | — | Conversion of Exercise of derivative security at price 7.90 per share. | KUNKEL LORI ANNE | Director | — | 2025-12-08 00:00:00 | D |
| 8 | 5534 | 20752.0 | — | Conversion of Exercise of derivative security at price 3.75 per share. | KUNKEL LORI ANNE | Director | — | 2025-12-04 00:00:00 | D |
| 9 | 37461 | 461520.0 | — | Sale at price 12.32 per share. | CHACKO JACOB M | Chief Executive Officer | — | 2025-10-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -141.79M | -109.75M | -80.80M | -77.97M |
| TotalUnusualItems | 0.00 | -5.00M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -5.00M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -127.85M | -100.70M | -89.12M | -78.72M |
| ReconciledDepreciation | 1.11M | 1.03M | 966.00K | 897.00K |
| EBITDA | -141.79M | -109.75M | -85.80M | -77.97M |
| EBIT | -142.90M | -110.78M | -86.77M | -78.87M |
| NetInterestIncome | 2.65M | 141.00K | ||
| InterestIncome | 2.65M | 141.00K | ||
| NormalizedIncome | -127.85M | -100.70M | -84.12M | -78.72M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -127.85M | -100.70M | -89.12M | -78.72M |
| TotalExpenses | 142.90M | 110.78M | 86.77M | 78.87M |
| TotalOperatingIncomeAsReported | -142.90M | -110.78M | -91.77M | -78.87M |
| DilutedAverageShares | 69.73M | 51.45M | 39.66M | 37.95M |
| BasicAverageShares | 69.73M | 51.45M | 39.66M | 37.95M |
| DilutedEPS | -1.83 | -1.96 | -2.25 | -2.07 |
| BasicEPS | -1.83 | -1.96 | -2.25 | -2.07 |
| DilutedNIAvailtoComStockholders | -127.85M | -100.70M | -89.12M | -78.72M |
| NetIncomeCommonStockholders | -127.85M | -100.70M | -89.12M | -78.72M |
| NetIncome | -127.85M | -100.70M | -89.12M | -78.72M |
| NetIncomeIncludingNoncontrollingInterests | -127.85M | -100.70M | -89.12M | -78.72M |
| NetIncomeContinuousOperations | -127.85M | -100.70M | -89.12M | -78.72M |
| PretaxIncome | -127.85M | -100.70M | -89.12M | -78.72M |
| OtherIncomeExpense | 15.05M | 10.08M | -2.35M | 15.00K |
| OtherNonOperatingIncomeExpenses | 15.05M | 10.08M | 2.65M | 15.00K |
| SpecialIncomeCharges | 0.00 | -5.00M | 0.00 | |
| OtherSpecialCharges | 5.00M | |||
| NetNonOperatingInterestIncomeExpense | 2.65M | 141.00K | ||
| InterestIncomeNonOperating | 2.65M | 141.00K | ||
| OperatingIncome | -142.90M | -110.78M | -86.77M | -78.87M |
| OperatingExpense | 142.90M | 110.78M | 86.77M | 78.87M |
| ResearchAndDevelopment | 114.07M | 85.17M | 61.68M | 56.86M |
| SellingGeneralAndAdministration | 28.82M | 25.61M | 25.09M | 22.01M |
| GeneralAndAdministrativeExpense | 28.82M | 25.61M | 25.09M | 22.01M |
| OtherGandA | 28.82M | 25.61M | 25.09M | 22.01M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 71.02M | 54.87M | 45.09M | 39.43M |
| ShareIssued | 71.02M | 54.87M | 45.09M | 39.43M |
| TotalDebt | 3.18M | 2.75M | 2.66M | 1.93M |
| TangibleBookValue | 243.12M | 224.09M | 222.35M | 272.98M |
| InvestedCapital | 243.12M | 224.09M | 222.35M | 272.98M |
| WorkingCapital | 237.40M | 192.14M | 195.07M | 225.37M |
| NetTangibleAssets | 243.12M | 224.09M | 222.35M | 272.98M |
| CapitalLeaseObligations | 3.18M | 2.75M | 2.66M | 1.93M |
| CommonStockEquity | 243.12M | 224.09M | 222.35M | 272.98M |
| TotalCapitalization | 243.12M | 224.09M | 222.35M | 272.98M |
| TotalEquityGrossMinorityInterest | 243.12M | 224.09M | 222.35M | 272.98M |
| StockholdersEquity | 243.12M | 224.09M | 222.35M | 272.98M |
| GainsLossesNotAffectingRetainedEarnings | 379.00K | 258.00K | -1.29M | -103.00K |
| OtherEquityAdjustments | 379.00K | 258.00K | -1.29M | -103.00K |
| RetainedEarnings | -562.77M | -434.93M | -334.23M | -245.11M |
| AdditionalPaidInCapital | 805.51M | 658.75M | 557.87M | 518.18M |
| CapitalStock | 7.00K | 6.00K | 5.00K | 4.00K |
| CommonStock | 7.00K | 6.00K | 5.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 31.02M | 27.92M | 24.83M | 25.67M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.17M | 7.46M | 9.44M | 10.52M |
| OtherNonCurrentLiabilities | 6.17M | 7.46M | 9.44M | 10.52M |
| CurrentLiabilities | 24.85M | 20.46M | 15.39M | 15.15M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 3.18M | 2.75M | 2.66M | 1.93M |
| CurrentCapitalLeaseObligation | 3.18M | 2.75M | 2.66M | 1.93M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.65M | 6.53M | 5.32M | 4.80M |
| PayablesAndAccruedExpenses | 14.02M | 11.18M | 7.41M | 8.43M |
| CurrentAccruedExpenses | 12.47M | 10.23M | 6.09M | 6.54M |
| Payables | 1.55M | 944.00K | 1.32M | 1.89M |
| AccountsPayable | 1.55M | 944.00K | 1.32M | 1.89M |
| TotalAssets | 274.14M | 252.01M | 247.18M | 298.64M |
| TotalNonCurrentAssets | 11.89M | 39.41M | 36.72M | 58.12M |
| OtherNonCurrentAssets | 8.97M | 9.70M | 11.52M | 12.32M |
| InvestmentsAndAdvances | 0.00 | 26.85M | 21.95M | 43.39M |
| InvestmentinFinancialAssets | 0.00 | 26.85M | 21.95M | 43.39M |
| AvailableForSaleSecurities | 26.85M | 21.95M | 43.39M | |
| NetPPE | 2.92M | 2.86M | 3.25M | 2.41M |
| AccumulatedDepreciation | -7.48M | -6.49M | -5.79M | -4.99M |
| GrossPPE | 10.40M | 9.36M | 9.05M | 7.40M |
| Leases | 2.04M | 1.97M | 1.98M | 1.71M |
| OtherProperties | 7.39M | 6.60M | 6.25M | 5.30M |
| MachineryFurnitureEquipment | 971.00K | 793.00K | 819.00K | 387.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 262.25M | 212.60M | 210.46M | 240.52M |
| OtherCurrentAssets | 6.29M | 4.41M | 4.18M | 3.54M |
| PrepaidAssets | 3.54M | |||
| CashCashEquivalentsAndShortTermInvestments | 255.96M | 208.19M | 206.27M | 236.98M |
| OtherShortTermInvestments | 196.55M | 184.80M | 139.43M | 10.97M |
| CashAndCashEquivalents | 59.41M | 23.38M | 66.84M | 226.01M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -113.85M | -86.54M | -77.22M | -60.48M |
| IssuanceOfCapitalStock | 125.00M | 85.00M | 25.00M | 50.00M |
| CapitalExpenditure | -1.19M | -849.00K | -2.08M | -939.00K |
| EndCashPosition | 59.90M | 23.88M | 67.31M | 226.47M |
| BeginningCashPosition | 23.88M | 67.31M | 226.47M | 78.45M |
| ChangesInCash | 36.02M | -43.43M | -159.17M | 148.03M |
| FinancingCashFlow | 126.55M | 85.66M | 25.23M | 49.13M |
| CashFlowFromContinuingFinancingActivities | 126.55M | 85.66M | 25.23M | 49.13M |
| NetOtherFinancingCharges | -168.00K | -227.00K | -399.00K | -1.85M |
| ProceedsFromStockOptionExercised | 1.72M | 885.00K | 624.00K | 986.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 125.00M | 85.00M | 25.00M | 50.00M |
| CommonStockIssuance | 125.00M | 85.00M | 25.00M | 50.00M |
| InvestingCashFlow | 22.14M | -43.40M | -109.25M | 158.44M |
| CashFlowFromContinuingInvestingActivities | 22.14M | -43.40M | -109.25M | 158.44M |
| NetInvestmentPurchaseAndSale | 23.32M | -42.55M | -107.17M | 159.37M |
| SaleOfInvestment | 275.25M | 196.69M | 130.95M | 229.00M |
| PurchaseOfInvestment | -251.92M | -239.24M | -238.12M | -69.63M |
| NetPPEPurchaseAndSale | -1.19M | -849.00K | -2.08M | -939.00K |
| PurchaseOfPPE | -1.19M | -849.00K | -2.08M | -939.00K |
| OperatingCashFlow | -112.66M | -85.69M | -75.14M | -59.54M |
| CashFlowFromContinuingOperatingActivities | -112.66M | -85.69M | -75.14M | -59.54M |
| ChangeInWorkingCapital | 1.97M | 4.90M | -445.00K | 4.07M |
| ChangeInPayablesAndAccruedExpense | 1.82M | 3.28M | -1.48M | 2.93M |
| ChangeInPayable | 2.93M | |||
| ChangeInAccountPayable | 2.93M | |||
| ChangeInPrepaidAssets | 143.00K | 1.62M | 1.03M | 1.14M |
| StockBasedCompensation | 20.21M | 15.23M | 14.46M | 12.85M |
| AmortizationOfSecurities | -8.10M | -6.17M | -1.04M | 1.35M |
| DepreciationAmortizationDepletion | 1.11M | 1.03M | 966.00K | 897.00K |
| DepreciationAndAmortization | 1.11M | 1.03M | 966.00K | 897.00K |
| Depreciation | 1.11M | 1.03M | 966.00K | 897.00K |
| OperatingGainsLosses | 22.00K | 40.00K | 2.00K | |
| GainLossOnSaleOfPPE | 0.00 | 22.00K | 40.00K | 2.00K |
| NetIncomeFromContinuingOperations | -127.85M | -100.70M | -89.12M | -78.72M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ORIC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|